ImageneBio Announces $30 Million Private Warrant Financing

ImageneBio ( (IMA) ) has provided an update.

On April 12, 2026, ImageneBio, Inc. entered into a Securities Purchase Agreement with institutional and accredited investors for a private placement of pre-funded warrants to purchase up to 5,770,335 shares of common stock at $5.199 per warrant share, for expected gross proceeds of about $30 million at closing anticipated around April 14, 2026. The company also agreed to a Registration Rights Agreement requiring it to register the resale of the warrant shares by investors and faces potential cash penalties for registration failures, while planning to use the net proceeds alongside existing cash to prepare for late-phase development in atopic dermatitis and to expand development of its IMG-007 candidate into additional indications, including alopecia areata.

The most recent analyst rating on (IMA) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on ImageneBio stock, see the IMA Stock Forecast page.

Spark’s Take on IMA Stock

According to Spark, TipRanks’ AI Analyst, IMA is a Neutral.

The score is driven primarily by weak financial performance (declining revenue to $0, widening losses, and ongoing cash burn), despite low leverage. Technicals add further pressure with a clear downtrend and negative MACD, though the stock is oversold. Valuation provides little support due to negative earnings and no dividend yield.

To see Spark’s full report on IMA stock, click here.

More about ImageneBio

ImageneBio, Inc. is a Delaware-based biopharmaceutical company focused on developing late-phase therapeutics in dermatology, including atopic dermatitis, and expanding indications for its pipeline candidate IMG-007 into immune-related skin conditions such as alopecia areata, targeting patients with significant unmet medical needs in these disease areas.

Average Trading Volume: 37,636

Technical Sentiment Signal: Sell

Current Market Cap: $54.83M

For an in-depth examination of IMA stock, go to TipRanks’ Overview page.